Zynerba goes into meltdown mode as cannabis-derived drug flops in PhII
Two years after its IPO, Devon, PA-based Zynerba Pharmaceuticals $ZYNE is grappling with the fallout from a failed Phase II study of its lead drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
